Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)

Market Cap	15.32B +30.4%
Revenue (ttm)	42.22M +22.5%
Net Income	-164.52M
EPS	-1.35
Shares Out	121.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,104,138
Open	121.50
Previous Close	120.50
Day's Range	119.50 - 128.00
52-Week Range	58.30 - 149.00
Beta	0.31
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Gongwin Biopharm Holdings

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company also develops animal medicines; engaged in the p...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6617

Financial Performance

In 2025, Gongwin Biopharm Holdings's revenue was 36.45 million, an increase of 13.75% compared to the previous year's 32.04 million. Losses were -114.13 million, 38.3% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 16, 2026

Data Sources Report a data error